Your browser doesn't support javascript.
loading
Population-based SEER trend analysis of overall and cancer-specific survival in 5138 patients with gastrointestinal stromal tumor.
Güller, Ulrich; Tarantino, Ignazio; Cerny, Thomas; Schmied, Bruno M; Warschkow, Rene.
Afiliação
  • Güller U; Division of Medical Oncology & Hematology, Kantonsspital St. Gallen, CH-9007, St. Gallen, Switzerland. Ulrich.Gueller@kssg.ch.
  • Tarantino I; University Clinic for Visceral Surgery and Medicine, University Hospital Berne, 3010, Berne, Switzerland. Ulrich.Gueller@kssg.ch.
  • Cerny T; Department of General, Abdominal and Transplant Surgery, University of Heidelberg, 69120, Heidelberg, Germany. Ignazio.Tarantino@med.uni-heidelberg.de.
  • Schmied BM; Division of Medical Oncology & Hematology, Kantonsspital St. Gallen, CH-9007, St. Gallen, Switzerland. Thomas.Cerny@kssg.ch.
  • Warschkow R; Department of Surgery, Kantonsspital St. Gallen, 9007, St. Gallen, Switzerland. Bruno.Schmied@kssg.ch.
BMC Cancer ; 15: 557, 2015 Jul 30.
Article em En | MEDLINE | ID: mdl-26223313
ABSTRACT

BACKGROUND:

The objective of the present population-based analysis was to assess survival patterns in patients with resected and metastatic GIST.

METHODS:

Patients with histologically proven GIST were extracted from the Surveillance, Epidemiology and End Results (SEER) database from 1998 through 2011. Survival was determined applying Kaplan-Meier-estimates and multivariable Cox-regression analyses. The impact of size and mitotic count on survival was assessed with a generalized receiver-operating characteristic-analysis.

RESULTS:

Overall, 5138 patients were included. Median age was 62 years (range 18-101 years), 47.3% were female, 68.8% Caucasians. GIST location was in the stomach in 58.7% and small bowel in 31.2%. Lymph node and distant metastases were found in 5.1 and 18.0%, respectively. For non-metastatic GIST, three-year overall survival increased from 68.5% (95 % CI 58.8-79.8%) in 1998 to 88.6% (95 % CI 85.3-92.0%) in 2008, cancer-specific survival from 75.3% (95 % CI 66.1-85.9%) in 1998 to 92.2% (95 % CI 89.4-95.1%) in 2008. For metastatic GIST, three-year overall survival increased from 15.0% (95 % CI 5.3-42.6%) in 1998 to 54.7% (95 % CI 44.4-67.3%) in 2008, cancer-specific survival from 15.0% (95 % CI 5.3-42.6%) in 1998 to 61.9% (95 % CI 51.4-74.5%) in 2008 (all PTrend < 0.05).

CONCLUSIONS:

This is the first SEER trend analysis assessing outcomes in a large cohort of GIST patients over a 11-year time period. The analysis provides compelling evidence of a statistically significant and clinically relevant increase in overall and cancer-specific survival from 1998 to 2008, both for resected as well as metastatic GIST.
Assuntos

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Tumores do Estroma Gastrointestinal / Neoplasias Gastrointestinais Limite: Adult / Aged / Aged80 / Female / Humans / Male / Middle aged Idioma: En Revista: BMC Cancer Assunto da revista: NEOPLASIAS Ano de publicação: 2015 Tipo de documento: Article País de afiliação: Suíça

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Tumores do Estroma Gastrointestinal / Neoplasias Gastrointestinais Limite: Adult / Aged / Aged80 / Female / Humans / Male / Middle aged Idioma: En Revista: BMC Cancer Assunto da revista: NEOPLASIAS Ano de publicação: 2015 Tipo de documento: Article País de afiliação: Suíça